TrialClinical ophthalmology (Auckland, N.Z.)2022

Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study.

Lee Shettle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.